Most genetic risk tools for Parkinson's disease were built on European and Asian cohort data — a foundational gap that quietly undermines diagnosis and drug development for billions of people. This large-scale sequencing study begins to correct that imbalance by mapping the protein-altering and splicing mutation landscape in individuals of African and African admixed ancestry, producing findings that diverge sharply from what clinicians currently rely on.
Analyzing 710 Parkinson's cases and nearly 12,000 controls drawn from genetically predicted African or African admixed ancestries, researchers found that GBA1 coding variants emerged as the most prevalent disease-associated mutations, appearing in roughly 4% of cases. Critically, the 18 GBA1 variants identified included four entirely novel mutations and several of uncertain clinical significance — and the canonical GBA1 variants well-characterized in Ashkenazi Jewish and European populations (p.Asn409Ser, p.Leu483Pro, p.Thr408Met, p.Glu365Lys) were entirely absent. The LRRK2 variants driving risk in European and Asian cohorts, including the widely screened p.Gly2019Ser, similarly showed negligible presence among West African ancestry participants. Instead, three novel heterozygous LRRK2 missense variants were detected, underscoring an ancestry-specific mutational architecture.
This is a genuinely important contribution to a field long criticized for Eurocentric bias. The practical implication is substantial: standard genetic panels used in neurological clinics, which screen for the well-known GBA1 and LRRK2 variants, would miss the majority of mutation carriers of African descent identified here. The study's exploration of copy number variants and runs of homozygosity in early-onset and familial cases adds further resolution. Limitations include the still-modest case count relative to the enormous African-ancestry population, and the heterogeneity across admixed groups. Nonetheless, this work is more than incremental — it provides an empirical foundation for ancestry-appropriate genetic counseling tools and for the design of Parkinson's trials that can claim genuine global relevance.